Compare Redwire Corporation (RDW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Redwire Corporation trades at $8.38 (market cap $2.29B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.1× Redwire Corporation's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Redwire Corporation for 18 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RDW | TVTX | |
|---|---|---|
Market Cap | $2.29B | $4.88B |
Volume | 9,800,070 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $25.90 | $67.52 |
52-Week Low | $5.06 | $26.79 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $1.82B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $9.16, down 0.65% on the day, showing bearish technical signals despite recent contract wins. The company reported strong revenue growth with Q2 2026 showing 89.6% year-over-year increase, but continues to post significant losses with a net income margin of -57.26%. Recent developments include a $981 million Space Force contract award and partnerships with Honda and Sophia Space for orbital infrastructure projects.
While analyst consensus remains bullish with an 80% buy rating and $14.88 price target, the stock faces substantial execution risks amid persistent losses and negative cash flow from operations. The company's growth trajectory depends heavily on successful contract execution and SpaceX's Starship development, making this a high-risk, high-potential investment in the emerging space economy.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
